G-protein gated Inwardly Rectifying K+ channel 4 (GIRK4) Genotyping
G-protein gated Inwardly Rectifying K+ channel 4 (GIRK4) belongs to the inward rectifier-type-potassium channel (TC 1.A.2.1) family and is coded by the KCNJ5 gene located at 11q24.3. GIRK4 is a G-protein coupled homotetrameric transmembrane ion transporter that is selective for potassium ions. Its function is to allow influx of potassium ions and prevent efflux. The produces an electrical gradient across the cell important for normal cellular functions GIRK4 is expressed in the adrenal glands as well as the heart, liver, spleen, and pituitary gland. Some of the physiologic functions of GIRK4 include atrial and ventricular repolarization, heartbeat regulation and regulation of aldosterone production by the adrenal cortex.
Mutations, primarily single amino acid substitutions in the transporter have been identified that alter the function of GIRK4 and are associated with Familial hyperaldosteronism Type III and approximately 40% of aldosterone-producing adenomas are associated with KCNJ5 mutations. In the adrenal adenomas the mutations decrease the specificity of the transporter and allow the entry of sodium. The subsequent change in transmembrane potential results in activation of calcium ion transporters and increased intracellular calcium levels. Elevated calcium activates a calcium/calmodulin-dependent pathway resulting in increased synthesis of aldosterone. However, the hypertension and hyperaldosteronism in this condition are not reversed by administration of glucocorticoids, differentiating it from primary aldosteronism.
KCNJ5 mutations have also been associated with Long QT syndrome 13 (LQTS13) which is characterized by QT prolongation and T-wave abnormalities on an EKG. Clinically, patients have ventricular tachycardia termed torsade de pointe (TdP) that may cause syncopal events associated with exercise and emotional stress. Long QT syndrome has been associated with pathogenic mutations in 15 different genes, most commonly KCHN2 (25-30%), KCNQ1 (30-35%), and SCN5A (5-10%). Mutations in KCNJ5 account for < 1% of cases.
Limited evidence suggests that genetic variations in GRIK4 are associated with certain psychiatric conditions such as bipolar affective disorder and schizophrenia. A genetic variantrs1954787 located in the 3’ region of the first intron of the GRIK4 gene has also been found to be predictive of antidepressant response and remission. The GRIK4 assay identifies the rs1954787 (c.83-10039T>C) variant that leads to altered function in kainic acid-type glutamate receptor and provides important information about clinical outcome with citalopram. The C allele occurs in 50% of Caucasians. The test is usually part of the Pharmacogenetic panel used for evaluation of psychotropic (antidepressants) therapy.
- As an aid in the diagnosis and management of hyperaldosteronism
- As an aid in differential diagnosis of Long QT syndrome
- Pharmacogenetics of antidepressants especially citalopram
Patients found to have KCJN5 mutations are at risk for hyperaldosteronism, adrenal adenoma and possible LQTS.
The rs1954787 (c.83-10039T>C) variant that leads to altered function in kainic acid-type glutamate receptor and provides important information about clinical outcome with citalopram.
c.83-10039T>C (rs19544787): T/T (Normal variant)
Whole blood, Lavender-top (EDTA) top tube, buccal swab.
Stability
- Ambient: 3-5 days
- Refrigerated: 7-14 days
- Frozen: 30 days
- Pharmacogenomics. 2013 Feb;14(3):277-88. [PMID: 23394390]
- Am J Psychiatry. 2007 Aug;164(8):1181-8. [PMID: 17671280]
- J Physiol. 2022 Mar;600(6):1419-1437. [PMID: 34957562]
- J Mol Endocrinol. 2021: 9;67(4):203-215 [PMID: 34463641]
- Hypertension. 201: 10;74(4):809-816 [PMID: 31446799]
- Rev. 2021;29(4):165-177 [PMID: 32947483]
- Ir Med J. 2014: 4;107(4):122-4 [PMID: 24834591]